| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Immunology |
Baylor Institute for Immunology Research, Dallas, Texas 75204 [J. B., A. K. P., S. B., N. T., A. R., S. T., S. C., L. P., J. F.]; Laboratory of Cellular Physiology and Immunology, The Rockefeller University, New York, New York 10021-6399 [M. D., N. B., R. S.]; and General Clinical Research Center, The Rockefeller University Hospital, New York, New York 10021-6399 [K. M. W.]
Immunization to multiple defined tumor antigens for specific immune therapy of human cancer has thus far proven difficult. Eighteen HLA A*0201+ patients with metastatic melanoma received injections s.c. of CD34+progenitor-derived autologous dendritic cells (DCs), which included Langerhans cells. DCs were pulsed with peptides derived from four melanoma antigens [(MelAgs) MelanA/MART-1, tyrosinase, MAGE-3, and gp100], as well as influenza matrix peptide (Flu-MP) and keyhole limpet hemocyanin (KLH) as control antigens. Overall immunological effects were assessed by comparing response profiles using marginal likelihood scores. DC injections were well tolerated except for progressive vitiligo in two patients. DCs induced an immune response to control antigens (KLH, Flu-MP) in 16 of 18 patients. An enhanced immune response to one or more MelAgs was seen in these same 16 patients, including 10 patients who responded to >2 MelAgs. The two patients failing to respond to both control and tumor antigens experienced rapid tumor progression. Of 17 patients with evaluable disease, 6 of 7 patients with immunity to two or less MelAgs had progressive disease 10 weeks after study entry, in contrast to tumor progression in only 1 of 10 patients with immunity to >2 MelAgs. Regression of >1 tumor metastases were observed in seven of these patients. The overall immunity to MelAgs after DC vaccination is associated with clinical outcome (P = 0.015).
This article has been cited by other articles:
![]() |
S. J. A. M. Santegoets, H. J. Bontkes, A. G. M. Stam, F. Bhoelan, J. J. Ruizendaal, A. J. M. van den Eertwegh, E. Hooijberg, R. J. Scheper, and T. D. de Gruijl Inducing Antitumor T Cell Immunity: Comparative Functional Analysis of Interstitial Versus Langerhans Dendritic Cells in a Human Cell Line Model J. Immunol., April 1, 2008; 180(7): 4540 - 4549. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Lengagne, S. Graff-Dubois, M. Garcette, L. Renia, M. Kato, J.-G. Guillet, V. H. Engelhard, M.-F. Avril, J.-P. Abastado, and A. Prevost-Blondel Distinct Role for CD8 T Cells toward Cutaneous Tumors and Visceral Metastases J. Immunol., January 1, 2008; 180(1): 130 - 137. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Vence, A. K. Palucka, J. W. Fay, T. Ito, Y.-J. Liu, J. Banchereau, and H. Ueno Circulating tumor antigen-specific regulatory T cells in patients with metastatic melanoma PNAS, December 26, 2007; 104(52): 20884 - 20889. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. K. Waller The Role of Sargramostim (rhGM-CSF) as Immunotherapy Oncologist, October 1, 2007; 12(suppl_2): 22 - 26. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Lizee, M. A. Cantu, and P. Hwu Less Yin, More Yang: Confronting the Barriers to Cancer Immunotherapy Clin. Cancer Res., September 15, 2007; 13(18): 5250 - 5255. [Abstract] [Full Text] [PDF] |
||||
![]() |
C Bauer, F Bauernfeind, A Sterzik, M Orban, M Schnurr, H A Lehr, S Endres, A Eigler, and M Dauer Dendritic cell-based vaccination combined with gemcitabine increases survival in a murine pancreatic carcinoma model Gut, September 1, 2007; 56(9): 1275 - 1282. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. J. A. M. Santegoets, M. W. J. Schreurs, A. W. Reurs, J. J. Lindenberg, E. W. M. Kueter, A. J. M. van den Eertwegh, E. Hooijberg, R. J. Brandwijk, S. E. Hufton, H. R. Hoogenboom, et al. Identification and Characterization of ErbB-3-Binding Protein-1 as a Target for Immunotherapy J. Immunol., August 1, 2007; 179(3): 2005 - 2012. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Michalek, I. Kocak, V. Fait, J. Zaloudik, and R. Hajek Detection and Long-Term In Vivo Monitoring of Individual Tumor-Specific T Cell Clones in Patients with Metastatic Melanoma J. Immunol., June 1, 2007; 178(11): 6789 - 6795. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. G. Molenkamp, B. J. R. Sluijter, B. Oosterhof, S. Meijer, and P. A. M. van Leeuwen Non-Radical Diagnostic Biopsies Do Not Negatively Influence Melanoma Patient Survival Ann. Surg. Oncol., April 1, 2007; 14(4): 1424 - 1430. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Paczesny, Y.-P. Li, N. Li, V. Latger-Cannard, L. Marchal, J.-P. Ou-Yang, P. Bordigoni, J.-F. Stoltz, and A. Eljaafari Efficient generation of CD34+ progenitor-derived dendritic cells from G-CSF-mobilized peripheral mononuclear cells does not require hematopoietic stem cell enrichment J. Leukoc. Biol., April 1, 2007; 81(4): 957 - 967. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. O. Weinzierl, C. Lemmel, O. Schoor, M. Muller, T. Kruger, D. Wernet, J. Hennenlotter, A. Stenzl, K. Klingel, H.-G. Rammensee, et al. Distorted Relation between mRNA Copy Number and Corresponding Major Histocompatibility Complex Ligand Density on the Cell Surface Mol. Cell. Proteomics, January 1, 2007; 6(1): 102 - 113. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Lesimple, E.-M. Neidhard, V. Vignard, C. Lefeuvre, H. Adamski, N. Labarriere, A. Carsin, D. Monnier, B. Collet, G. Clapisson, et al. Immunologic and Clinical Effects of Injecting Mature Peptide-Loaded Dendritic Cells by Intralymphatic and Intranodal Routes in Metastatic Melanoma Patients Clin. Cancer Res., December 15, 2006; 12(24): 7380 - 7388. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. A. Blocki, S. Radhakrishnan, V. P. Van Keulen, K. L. Heckman, B. Ciric, C. L. Howe, M. Rodriguez, E. Kwon, and L. R. Pease Induction of a gene expression program in dendritic cells with a cross-linking IgM antibody to the co-stimulatory molecule B7-DC FASEB J, November 1, 2006; 20(13): 2408 - 2410. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Grover, G. J. Kim, G. Lizee, M. Tschoi, G. Wang, J. R. Wunderlich, S. A. Rosenberg, S. T. Hwang, and P. Hwu Intralymphatic dendritic cell vaccination induces tumor antigen-specific, skin-homing T lymphocytes. Clin. Cancer Res., October 1, 2006; 12(19): 5801 - 5808. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Schott Immunesurveillance by dendritic cells: potential implication for immunotherapy of endocrine cancers. Endocr. Relat. Cancer, September 1, 2006; 13(3): 779 - 795. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Wierecky, M. R. Muller, S. Wirths, E. Halder-Oehler, D. Dorfel, S. M. Schmidt, M. Hantschel, W. Brugger, S. Schroder, M. S. Horger, et al. Immunologic and Clinical Responses after Vaccinations with Peptide-Pulsed Dendritic Cells in Metastatic Renal Cancer Patients Cancer Res., June 1, 2006; 66(11): 5910 - 5918. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. J.C.L.M. Vuylsteke, B. G. Molenkamp, P. A.M. van Leeuwen, S. Meijer, P. G.J.T.B. Wijnands, J. B.A.G. Haanen, R. J. Scheper, and T. D. de Gruijl Tumor-Specific CD8+ T Cell Reactivity in the Sentinel Lymph Node of GM-CSF-Treated Stage I Melanoma Patients is Associated with High Myeloid Dendritic Cell Content. Clin. Cancer Res., May 1, 2006; 12(9): 2826 - 2833. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. H. Schuurhuis, N. van Montfoort, A. Ioan-Facsinay, R. Jiawan, M. Camps, J. Nouta, C. J. M. Melief, J. S. Verbeek, and F. Ossendorp Immune complex-loaded dendritic cells are superior to soluble immune complexes as antitumor vaccine. J. Immunol., April 15, 2006; 176(8): 4573 - 4580. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. I. Slukvin, M. A. Vodyanik, J. A. Thomson, M. E. Gumenyuk, and K.-D. Choi Directed Differentiation of Human Embryonic Stem Cells into Functional Dendritic Cells through the Myeloid Pathway. J. Immunol., March 1, 2006; 176(5): 2924 - 2932. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Otsu, K. Gotoh, T. Yamashiro, J. Yamagata, K. Shin, T. Fujioka, and A. Nishizono Transfer of Antigen-Pulsed Dendritic Cells Induces Specific T-Cell Proliferation and a Therapeutic Effect against Long-Term Helicobacter pylori Infection in Mice Infect. Immun., February 1, 2006; 74(2): 984 - 993. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. V. DHODAPKAR Immune Response to Premalignancy: Insights from Patients with Monoclonal Gammopathy Ann. N.Y. Acad. Sci., December 1, 2005; 1062(1): 22 - 28. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Lennerz, M. Fatho, C. Gentilini, R. A. Frye, A. Lifke, D. Ferel, C. Wolfel, C. Huber, and T. Wolfel The response of autologous T cells to a human melanoma is dominated by mutated neoantigens PNAS, November 1, 2005; 102(44): 16013 - 16018. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. P. Moran, M. Collier, K. P. McKinnon, N. L. Davis, R. E. Johnston, and J. S. Serody A Novel Viral System for Generating Antigen-Specific T Cells J. Immunol., September 1, 2005; 175(5): 3431 - 3438. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Bertho, H. Adamski, L. Toujas, M. Debove, J. Davoust, and V. Quillien Efficient migration of dendritic cells toward lymph node chemokines and induction of TH1 responses require maturation stimulus and apoptotic cell interaction Blood, September 1, 2005; 106(5): 1734 - 1741. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Mahnke, Y. Qian, S. Fondel, J. Brueck, C. Becker, and A. H. Enk Targeting of Antigens to Activated Dendritic Cells In vivo Cures Metastatic Melanoma in Mice Cancer Res., August 1, 2005; 65(15): 7007 - 7012. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Rossi and J. W. Young Human Dendritic Cells: Potent Antigen-Presenting Cells at the Crossroads of Innate and Adaptive Immunity J. Immunol., August 1, 2005; 175(3): 1373 - 1381. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. M. Liau, R. M. Prins, S. M. Kiertscher, S. K. Odesa, T. J. Kremen, A. J. Giovannone, J.-W. Lin, D. J. Chute, P. S. Mischel, T. F. Cloughesy, et al. Dendritic Cell Vaccination in Glioblastoma Patients Induces Systemic and Intracranial T-cell Responses Modulated by the Local Central Nervous System Tumor Microenvironment Clin. Cancer Res., August 1, 2005; 11(15): 5515 - 5525. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. A. Jungbluth, S. Ely, M. DiLiberto, R. Niesvizky, B. Williamson, D. Frosina, Y.-T. Chen, N. Bhardwaj, S. Chen-Kiang, L. J. Old, et al. The cancer-testis antigens CT7 (MAGE-C1) and MAGE-A3/6 are commonly expressed in multiple myeloma and correlate with plasma-cell proliferation Blood, July 1, 2005; 106(1): 167 - 174. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Dieckmann, E. S. Schultz, B. Ring, P. Chames, G. Held, H. R. Hoogenboom, and G. Schuler Optimizing the exogenous antigen loading of monocyte-derived dendritic cells Int. Immunol., May 1, 2005; 17(5): 621 - 635. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. H. Tien, L. Xu, and C. D. Helgason Altered Immunity Accompanies Disease Progression in a Mouse Model of Prostate Dysplasia Cancer Res., April 1, 2005; 65(7): 2947 - 2955. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. J. Prasad, K. J. Farrand, S. A. Matthews, J. H. Chang, R. S. McHugh, and F. Ronchese Dendritic Cells Loaded with Stressed Tumor Cells Elicit Long-Lasting Protective Tumor Immunity in Mice Depleted of CD4+CD25+ Regulatory T Cells J. Immunol., January 1, 2005; 174(1): 90 - 98. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Parmiani, A. Testori, M. Maio, C. Castelli, L. Rivoltini, L. Pilla, F. Belli, V. Mazzaferro, J. Coppa, R. Patuzzo, et al. Heat Shock Proteins and Their Use as Anticancer Vaccines Clin. Cancer Res., December 15, 2004; 10(24): 8142 - 8146. [Full Text] [PDF] |
||||
![]() |
F. Ito, Q. Li, A. B. Shreiner, R. Okuyama, M. N. Jure-Kunkel, S. Teitz-Tennenbaum, and A. E. Chang Anti-CD137 Monoclonal Antibody Administration Augments the Antitumor Efficacy of Dendritic Cell-Based Vaccines Cancer Res., November 15, 2004; 64(22): 8411 - 8419. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. J. C. L. M. Vuylsteke, B. G. Molenkamp, H. A. Gietema, P. A. M. van Leeuwen, P. G. J. T. B. Wijnands, W. Vos, P. J. van Diest, R. J. Scheper, S. Meijer, and T. D. de Gruijl Local Administration of Granulocyte/Macrophage Colony-stimulating Factor Increases the Number and Activation State of Dendritic Cells in the Sentinel Lymph Node of Early-Stage Melanoma Cancer Res., November 15, 2004; 64(22): 8456 - 8460. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Sakai, B. J. Morrison, J. D. Burke, J.-M. Park, M. Terabe, J. E. Janik, G. Forni, J. A. Berzofsky, and J. C. Morris Vaccination by Genetically Modified Dendritic Cells Expressing a Truncated neu Oncogene Prevents Development of Breast Cancer in Transgenic Mice Cancer Res., November 1, 2004; 64(21): 8022 - 8028. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Cloosen, M. Thio, A. Vanclee, E. B. M. van Leeuwen, B. L. M. G. Senden-Gijsbers, E. B. H. Oving, W. T. V. Germeraad, and G. M. J. Bos Mucin-1 is expressed on dendritic cells, both in vitro and in vivo Int. Immunol., November 1, 2004; 16(11): 1561 - 1571. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. W. O'Neill, S. Adams, and N. Bhardwaj Manipulating dendritic cell biology for the active immunotherapy of cancer Blood, October 15, 2004; 104(8): 2235 - 2246. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Avigan Dendritic Cell-Tumor Fusion Vaccines for Renal Cell Carcinoma Clin. Cancer Res., September 15, 2004; 10(18): 6347S - 6352S. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Ratzinger, J. Baggers, M. A. de Cos, J. Yuan, T. Dao, J. L. Reagan, C. Munz, G. Heller, and J. W. Young Mature Human Langerhans Cells Derived from CD34+ Hematopoietic Progenitors Stimulate Greater Cytolytic T Lymphocyte Activity in the Absence of Bioactive IL-12p70, by Either Single Peptide Presentation or Cross-Priming, Than Do Dermal-Interstitial or Monocyte-Derived Dendritic Cells J. Immunol., August 15, 2004; 173(4): 2780 - 2791. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Di Nicola, C. Carlo-Stella, R. Mortarini, P. Baldassari, A. Guidetti, G. F. Gallino, M. Del Vecchio, F. Ravagnani, M. Magni, P. Chaplin, et al. Boosting T Cell-Mediated Immunity to Tyrosinase by Vaccinia Virus-Transduced, CD34+-Derived Dendritic Cell Vaccination: A Phase I Trial in Metastatic Melanoma Clin. Cancer Res., August 15, 2004; 10(16): 5381 - 5390. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Viguier, F. Lemaitre, O. Verola, M.-S. Cho, G. Gorochov, L. Dubertret, H. Bachelez, P. Kourilsky, and L. Ferradini Foxp3 Expressing CD4+CD25high Regulatory T Cells Are Overrepresented in Human Metastatic Melanoma Lymph Nodes and Inhibit the Function of Infiltrating T Cells J. Immunol., July 15, 2004; 173(2): 1444 - 1453. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Mocellin, E. Wang, M. Panelli, P. Pilati, and F. M. Marincola DNA Array-Based Gene Profiling in Tumor Immunology Clin. Cancer Res., July 15, 2004; 10(14): 4597 - 4606. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Avigan, B. Vasir, J. Gong, V. Borges, Z. Wu, L. Uhl, M. Atkins, J. Mier, D. McDermott, T. Smith, et al. Fusion Cell Vaccination of Patients with Metastatic Breast and Renal Cancer Induces Immunological and Clinical Responses Clin. Cancer Res., July 15, 2004; 10(14): 4699 - 4708. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Nencioni and P. Brossart Cellular Immunotherapy with Dendritic Cells in Cancer: Current Status Stem Cells, July 1, 2004; 22(4): 501 - 513. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Ebstein, C. Sapede, P.-J. Royer, M. Marcq, C. Ligeza-Poisson, I. Barbieux, L. Cellerin, G. Dabouis, and M. Gregoire Cytotoxic T Cell Responses against Mesothelioma by Apoptotic Cell-pulsed Dendritic Cells Am. J. Respir. Crit. Care Med., June 15, 2004; 169(12): 1322 - 1330. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Paczesny, J. Banchereau, K. M. Wittkowski, G. Saracino, J. Fay, and A. K. Palucka Expansion of Melanoma-specific Cytolytic CD8+ T Cell Precursors in Patients with Metastatic Melanoma Vaccinated with CD34+ Progenitor-derived Dendritic Cells J. Exp. Med., June 7, 2004; 199(11): 1503 - 1511. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Schrama, R. Xiang, A. O. Eggert, M. H. Andersen, L. O. Pedersen, E. Kampgen, T. N. Schumacher, R. R. Reisfeld, and J. C. Becker Shift from Systemic to Site-Specific Memory by Tumor-Targeted IL-2 J. Immunol., May 15, 2004; 172(10): 5843 - 5850. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. J. Ullenhag, J.-E. Frodin, M. Jeddi-Tehrani, K. Strigard, E. Eriksson, A. Samanci, A. Choudhury, B. Nilsson, E. D. Rossmann, S. Mosolits, et al. Durable Carcinoembryonic Antigen (CEA)-Specific Humoral and Cellular Immune Responses in Colorectal Carcinoma Patients Vaccinated with Recombinant CEA and Granulocyte/Macrophage Colony-Stimulating Factor Clin. Cancer Res., May 15, 2004; 10(10): 3273 - 3281. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Rouas, P. Lewalle, F. El Ouriaghli, B. Nowak, H. Duvillier, and P. Martiat Poly(I:C) used for human dendritic cell maturation preserves their ability to secondarily secrete bioactive IL-12 Int. Immunol., May 1, 2004; 16(5): 767 - 773. [Abstract] [Full Text] [PDF] |
||||
![]() |
K.-J. Liu, C.-C. Wang, L.-T. Chen, A.-L. Cheng, D.-T. Lin, Y.-C. Wu, W.-L. Yu, Y.-M. Hung, H.-Y. Yang, S.-H. Juang, et al. Generation of Carcinoembryonic Antigen (CEA)-Specific T-Cell Responses in HLA-A*0201 and HLA-A*2402 Late-Stage Colorectal Cancer Patients after Vaccination with Dendritic Cells Loaded with CEA Peptides Clin. Cancer Res., April 15, 2004; 10(8): 2645 - 2651. [Abstract] [Full Text] [PDF] |
||||
![]() |
S.-C. Yang, S. Hillinger, K. Riedl, L. Zhang, L. Zhu, M. Huang, K. Atianzar, B. Y. Kuo, B. Gardner, R. K. Batra, et al. Intratumoral Administration of Dendritic Cells Overexpressing CCL21 Generates Systemic Antitumor Responses and Confers Tumor Immunity Clin. Cancer Res., April 15, 2004; 10(8): 2891 - 2901. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Yang and F. G. Haluska Treatment of Melanoma with 5-Fluorouracil or Dacarbazine In Vitro Sensitizes Cells to Antigen-Specific CTL Lysis through Perforin/Granzyme- and Fas-Mediated Pathways J. Immunol., April 1, 2004; 172(7): 4599 - 4608. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Chen, S. Antonenko, J. M. Sederstrom, X. Liang, A. S. H. Chan, H. Kanzler, B. Blom, B. R. Blazar, and Y.-J. Liu Thrombopoietin cooperates with FLT3-ligand in the generation of plasmacytoid dendritic cell precursors from human hematopoietic progenitors Blood, April 1, 2004; 103(7): 2547 - 2553. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Vertuani, A. Sette, J. Sidney, S. Southwood, J. Fikes, E. Keogh, J. A. Lindencrona, G. Ishioka, J. Levitskaya, and R. Kiessling Improved Immunogenicity of an Immunodominant Epitope of the Her-2/neu Protooncogene by Alterations of MHC Contact Residues J. Immunol., March 15, 2004; 172(6): 3501 - 3508. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. M. Coughlin, B. A. Vance, S. A. Grupp, and R. H. Vonderheide RNA-transfected CD40-activated B cells induce functional T-cell responses against viral and tumor antigen targets: implications for pediatric immunotherapy Blood, March 15, 2004; 103(6): 2046 - 2054. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Atanackovic, N. K. Altorki, E. Stockert, B. Williamson, A. A. Jungbluth, E. Ritter, D. Santiago, C. A. Ferrara, M. Matsuo, A. Selvakumar, et al. Vaccine-Induced CD4+ T Cell Responses to MAGE-3 Protein in Lung Cancer Patients J. Immunol., March 1, 2004; 172(5): 3289 - 3296. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Kuang, B. G. Peng, M. D. Lu, L. J. Liang, J. F. Huang, Q. He, Y. P. Hua, S. Totsuka, S. Q. Liu, K. W. Leong, et al. Phase II Randomized Trial of Autologous Formalin-Fixed Tumor Vaccine for Postsurgical Recurrence of Hepatocellular Carcinoma Clin. Cancer Res., March 1, 2004; 10(5): 1574 - 1579. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Taieb, K. Maruyama, C. Borg, M. Terme, L. Zitvogel, S. Appel, and P. Brossart Imatinib mesylate impairs Flt3L-mediated dendritic cell expansion and antitumor effects in vivo Blood, March 1, 2004; 103(5): 1966 - 1967. |